Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Liquid Biopsy System (LBS): Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
Study summary
The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. Using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.
Eligibility
Primary outcome measure(s)
- Trans-plaque gradients (downstream value divided by upstream value) for LOX-1 and CXCL1 — Single time point (time of intervention)
- Liquid Biopsy System (LBS) performance: successful positioning and successful intracoronary sampling — Single time point (time of intervention)
Success define as confirmed adequate positioning of the device across the identified lesion of interest and collection of sufficient whole blood from each functional port to generate \>100µl plasma once processed
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Royal Bournemouth Hospital | Bournemouth | United Kingdom | Recruiting |
| Bristol Heart Institute | Bristol | United Kingdom | Recruiting |
| Royal Papworth Hospital | Cambridge | United Kingdom | Recruiting |
| Norfolk and Norwich Hospital | Norwich | United Kingdom | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06259019 on ClinicalTrials.gov ↗ ← All trials in the UK